Euroapi

Euroapi EBIT Growth

The Year-over-Year EBIT Growth of Euroapi (EAPI.PA) as of Oct 17, 2026 is 100.18 %. In the previous year, Year-over-Year EBIT Growth was 52.43 % — a change of 91.07% (higher).

EBIT Growth

100.18 %

YoY

91.07%

Last updated:

Year-over-Year EBIT Growth of Euroapi is 2025 100.18 % . Year-over-Year EBIT Growth of Euroapi was 2024 52.43 % . It decreases by 91.07% higher compared to the previous year.

The Euroapi EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2020
-395.45 EUR
Jan 1, 2021
124.77 EUR
Jan 1, 2022
-129.63 EUR
Jan 1, 2023
-29,200.00 EUR
Jan 1, 2024
52.43 EUR
Jan 1, 2025
100.18 EUR
The Euroapi EBIT Growth history
YEAREBIT GrowthYoY
100.18 %+91.07%
52.43 %-100.18%
-29,200.00 %+22,425.71%
-129.63 %-203.89%
124.77 %-131.55%
-395.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Euroapi Stock analysis

What does Euroapi do? Euroapi SA, listed on EAPI.PA with ISIN FR0014008VX5, is a pharmaceutical company headquartered in Paris, France. The company went public on May 6, 2022, and currently employs 3,449 full-time staff. Euroapi specializes in the development, manufacture, and supply of active pharmaceutical ingredients (APIs) for healthcare partners. Its product portfolio includes vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids, hormones, anti-infectives, opiates such as morphine, codeine, and thebaine, and analgesics. The company operates as a Contract Development and Manufacturing Organization (CDMO), offering services such as Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones, and Opiates & Controlled Substances. Euroapi maintains production facilities across multiple European countries, including France, the United Kingdom, Germany, Italy, and Hungary. The company's website is www.euroapi.com, where further information about its services and operations can be found. Euroapi focuses on providing tailored API solutions to support the pharmaceutical industry's needs, emphasizing its role in the healthcare sector through its specialized manufacturing capabilities. Euroapi is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Euroapi stock

Year-over-Year EBIT Growth of Euroapi is 100.18 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Euroapi since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Euroapi historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Euroapi

All Key Metrics — Euroapi